RECEPTOR.AI

About:

RECEPTOR.AI - drug discovery for precision medecine

Website: https://receptor.ai/

Twitter/X: receptorai

Top Investors: Campus

Description:

Receptor.AI is committed to pushing the boundaries of precision medicine by developing a pipeline of novel small molecules that possess ultimate selectivity in targeting highly similar disease-related proteins such as homologs, mutants, isoforms, and allele variations. Our proprietary five-level selectivity assessment engine is designed to laser-focus on protein variants specific to particular human populations, organs, tissues and tumour types, ensuring precise alignment with patient profiles. Receptor.AI platform combines experimental structure determination techniques and AI-augmented medicinal chemistry, unlocking allosteric and cryptic binding pockets and unravelling protein conformational flexibility, making it possible to discriminate between otherwise indistinguishable targets and off-targets.

Total Funding Amount:

$500000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2021-02-01

Contact Email:

ai(AT)receptor.ai

Founders:

Alan Nafiiev, Semen Yesylevskyy, Sergii Starosyla

Number of Employees:

11-50

Last Funding Date:

2022-12-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai